Literature DB >> 33827115

CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion.

Yun Deng1, Bithi Chatterjee1, Kyra Zens1,2, Hana Zdimerova1, Anne Müller1, Patrick Schuhmachers1, Laure-Anne Ligeon1, Antonino Bongiovanni3,4, Riccarda Capaul5, Andrea Zbinden5, Angelika Holler6, Hans Stauss6, Wolfgang Hammerschmidt7, Christian Münz1.   

Abstract

Primary immunodeficiencies in the costimulatory molecule CD27 and its ligand, CD70, predispose for pathologies of uncontrolled Epstein-Barr virus (EBV) infection in nearly all affected patients. We demonstrate that both depletion of CD27+ cells and antibody blocking of CD27 interaction with CD70 cause uncontrolled EBV infection in mice with reconstituted human immune system components. While overall CD8+ T-cell expansion and composition are unaltered after antibody blocking of CD27, only some EBV-specific CD8+ T-cell responses, exemplified by early lytic EBV antigen BMLF1-specific CD8+ T cells, are inhibited in their proliferation and killing of EBV-transformed B cells. This suggests that CD27 is not required for all CD8+ T-cell expansions and cytotoxicity but is required for a subset of CD8+ T-cell responses that protect us from EBV pathology.
© 2021 by The American Society of Hematology.

Entities:  

Keywords:  CD27; CD39; DLBCL; Epstein-Barr virus; IMMUNOBIOLOGY/B-cell neoplasms; IMMUNOBIOLOGY/Cytotoxic T cells; IMMUNOBIOLOGY/Host-pathogen interactions; IMMUNOBIOLOGY/T-Cell Mediated Immunity; IMMUNOBIOLOGY/T-cell costimulation; humanized mice

Mesh:

Substances:

Year:  2021        PMID: 33827115      PMCID: PMC8351885          DOI: 10.1182/blood.2020009482

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.

Authors:  M A EPSTEIN; B G ACHONG; Y M BARR
Journal:  Lancet       Date:  1964-03-28       Impact factor: 79.321

2.  The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.

Authors:  P Bertrand; C Maingonnat; D Penther; S Guney; P Ruminy; J M Picquenot; S Mareschal; M Alcantara; A Bouzelfen; S Dubois; M Figeac; C Bastard; H Tilly; F Jardin
Journal:  Genes Chromosomes Cancer       Date:  2013-05-28       Impact factor: 5.006

3.  CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.

Authors:  Joris M van Montfrans; Andy I M Hoepelman; Sigrid Otto; Marielle van Gijn; Lisette van de Corput; Roel A de Weger; Linda Monaco-Shawver; Pinaki P Banerjee; Elisabeth A M Sanders; Cornelia M Jol-van der Zijde; Michael R Betts; Jordan S Orange; Andries C Bloem; Kiki Tesselaar
Journal:  J Allergy Clin Immunol       Date:  2011-12-24       Impact factor: 10.793

Review 4.  SLAM family receptors and SAP adaptors in immunity.

Authors:  Jennifer L Cannons; Stuart G Tangye; Pamela L Schwartzberg
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

5.  Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors.

Authors:  G J Babcock; D A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 6.  Epstein-Barr virus: 40 years on.

Authors:  Lawrence S Young; Alan B Rickinson
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

7.  Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D.

Authors:  Benjamin Chaigne-Delalande; Feng-Yen Li; Geraldine M O'Connor; Marshall J Lukacs; Ping Jiang; Lixin Zheng; Amber Shatzer; Matthew Biancalana; Stefania Pittaluga; Helen F Matthews; Timothy J Jancel; Jack J Bleesing; Rebecca A Marsh; Taco W Kuijpers; Kim E Nichols; Carrie L Lucas; Sunil Nagpal; Huseyin Mehmet; Helen C Su; Jeffrey I Cohen; Gulbu Uzel; Michael J Lenardo
Journal:  Science       Date:  2013-07-12       Impact factor: 47.728

Review 8.  Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection.

Authors:  Stuart G Tangye; Sylvain Latour
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

9.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

10.  Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection.

Authors:  Paulina Mrozek-Gorska; Alexander Buschle; Dagmar Pich; Thomas Schwarzmayr; Ron Fechtner; Antonio Scialdone; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-24       Impact factor: 11.205

View more
  7 in total

1.  Interleukin-35 has a Protective Role in Infectious Mononucleosis-Induced Liver Inflammation Probably by Inhibiting CD8+ T Cell Function.

Authors:  Ying Gao; Lan Li; Xingxing Hu; Weihua Zhang; Yu Li
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-10-11       Impact factor: 3.831

Review 2.  Epstein-Barr virus and multiple sclerosis.

Authors:  Samantha S Soldan; Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2022-08-05       Impact factor: 78.297

3.  Prognostic impacts of soluble immune checkpoint regulators and cytokines in patients with SARS-CoV-2 infection.

Authors:  Nuri Lee; Seri Jeong; Kibum Jeon; Min-Jeong Park; Wonkeun Song
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

4.  Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

Authors:  Tilman Schneider-Hohendorf; Lisa Ann Gerdes; Béatrice Pignolet; Roland Liblau; Heinz Wiendl; Nicholas Schwab; Rachel Gittelman; Patrick Ostkamp; Florian Rubelt; Catarina Raposo; Björn Tackenberg; Marianne Riepenhausen; Claudia Janoschka; Christian Wünsch; Florence Bucciarelli; Andrea Flierl-Hecht; Eduardo Beltrán; Tania Kümpfel; Katja Anslinger; Catharina C Gross; Heidi Chapman; Ian Kaplan; David Brassat; Hartmut Wekerle; Martin Kerschensteiner; Luisa Klotz; Jan D Lünemann; Reinhard Hohlfeld
Journal:  J Exp Med       Date:  2022-09-01       Impact factor: 17.579

Review 5.  Natural Killer Cell Responses during Human γ-Herpesvirus Infections.

Authors:  Christian Münz
Journal:  Vaccines (Basel)       Date:  2021-06-15

Review 6.  Roles of Lytic Viral Replication and Co-Infections in the Oncogenesis and Immune Control of the Epstein-Barr Virus.

Authors:  Yun Deng; Christian Münz
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

Review 7.  Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection.

Authors:  Christian Münz
Journal:  Biomolecules       Date:  2021-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.